Dupixent Approved in Japan as the First Targeted Therapy for Adults with Bullous Pemphigoid Regeneron Pharmaceuticals and Sanofi have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for Dupixent as a treatment for adults suffering…
Eylea™ 8 mg Secures Approval in Japan for Its Third Retinal Disease Indication The Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorization in Japan for Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for…
Pfizer and Valneva Report Positive Phase 3 VALOR Results Showing High Efficacy for Lyme Disease Vaccine Candidate Pfizer Inc. and Valneva SE have announced encouraging topline findings from the pivotal Phase 3 VALOR clinical trial evaluating their investigational Lyme disease…
Curi Bio and Battelle Forge Strategic Alliance to Advance New Approach Methods in Neuromuscular Pharmacology Curi Bio, a recognized leader in the development of human-relevant three-dimensional (3D) tissue platforms, has entered into a strategic partnership with Battelle, the world’s largest…
Newron Showcases Latest Research at the 2026 Schizophrenia International Research Society Annual Congress 2026 Newron Pharmaceuticals S.p.A., a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for disorders affecting the central and peripheral nervous systems, has announced its active participation…
Novo Nordisk A/S: Wegovy® HD (7.2 mg) gains US approval, delivering 20.7% average weight reduction Novo Nordisk has reached another major milestone in the treatment of obesity, announcing that the U.S. Food and Drug Administration (FDA) has granted approval for…
ICON plc announces revised timeline for Q4 and full-year 2025 earnings as investigation into accounting practices continues. ICON plc, today announced that it intends to release its fourth quarter and full year 2025 earnings results on or prior to April 30,…
Novartis’s Cosentyx gains U.S. Food and Drug Administration approval for patients aged 12+ with moderate-to-severe Hidradenitis Suppurativa. Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis…
WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Advancements in Bioprocessing, Manufacturing Quality, and Digital Innovation WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards…
Johnson & Johnson Secures U.S. Food and Drug Administration Approval for TECNIS PureSee Intraocular Lens, Expanding Vision Care Options for U.S. Cataract Patients Johnson & Johnson announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth…
GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications GoodRx the leading platform for prescription savings in the U.S., announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established…
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan Curatis Holding AG and Neupharma Co., Ltd. a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology…